Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. The comapny engages in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome. It has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.
Stock data | 2024 | Change |
---|---|---|
Price | $0.021 | N/A |
Market Cap | $3.09M | N/A |
Shares Outstanding | 147.17M | N/A |
Employees | 0 | N/A |